Activation of the complement cascade of proteases has been linked to autoimmune and kidney diseases, including systemic lupus ...
The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary humoral immunodeficiency, according to a company press release. “Primary ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Early broadly neutralising antibody responses against the E1E2 glycoprotein seem to be important for preventing persistence ...
QIVIGY is the realization of over 10 years of investments and internal efforts to bring a proprietary IVIG product from concept to commercialization FORT LEE, N.J., Sept. 29, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback